Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
ClinicalTrials.gov ID NCT03388632
Sponsor National Cancer Institute (NCI)
Information provided by National Institutes of Health Clinical Center (CC) (National Cancer Institute (NCI)) (Responsible Party)